These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35882665)

  • 21. Alpha Synuclein: Neurodegeneration and Inflammation.
    Forloni G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
    Peng C; Gathagan RJ; Lee VM
    Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRP1 is a neuronal receptor for α-synuclein uptake and spread.
    Chen K; Martens YA; Meneses A; Ryu DH; Lu W; Raulin AC; Li F; Zhao J; Chen Y; Jin Y; Linares C; Goodwin M; Li Y; Liu CC; Kanekiyo T; Holtzman DM; Golde TE; Bu G; Zhao N
    Mol Neurodegener; 2022 Sep; 17(1):57. PubMed ID: 36056345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
    Kalsoom I; Wang Y; Li B; Wen H
    Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The good and bad of therapeutic strategies that directly target α-synuclein.
    Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
    IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
    Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
    J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies.
    Huang J; Yuan X; Chen L; Hu B; Wang H; Wang Y; Huang W
    Exp Gerontol; 2024 Mar; 187():112366. PubMed ID: 38280659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysophospholipids-potent candidates for brain food, protects neuronal cells against α-Synuclein aggregation.
    Karaki T; Haniu H; Matsuda Y; Tsukahara T
    Biomed Pharmacother; 2022 Dec; 156():113891. PubMed ID: 36265307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
    Bellomo G; De Luca CMG; Paoletti FP; Gaetani L; Moda F; Parnetti L
    Neurology; 2022 Aug; 99(5):195-205. PubMed ID: 35914941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease.
    Kasen A; Houck C; Burmeister AR; Sha Q; Brundin L; Brundin P
    Neurobiol Dis; 2022 May; 166():105654. PubMed ID: 35143968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.
    Rockenstein E; Ostroff G; Dikengil F; Rus F; Mante M; Florio J; Adame A; Trinh I; Kim C; Overk C; Masliah E; Rissman RA
    J Neurosci; 2018 Jan; 38(4):1000-1014. PubMed ID: 29246926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
    Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
    Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells.
    Kim C; Kwon S; Iba M; Spencer B; Rockenstein E; Mante M; Adame A; Shin SJ; Fields JA; Rissman RA; Lee SJ; Masliah E
    Exp Mol Med; 2021 Feb; 53(2):281-290. PubMed ID: 33594256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death.
    Mahul-Mellier AL; Vercruysse F; Maco B; Ait-Bouziad N; De Roo M; Muller D; Lashuel HA
    Cell Death Differ; 2015 Dec; 22(12):2107-22. PubMed ID: 26138444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of an α-synuclein fibril and oligomer specific tracer for diagnosis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy.
    Sevenich M; Honold D; Willuweit A; Kutzsche J; Mohrlüder J; Willbold D
    Neurochem Int; 2022 Dec; 161():105422. PubMed ID: 36252819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA.
    Becker K; Wang X; Vander Stel K; Chu Y; Kordower J; Ma J
    Mol Neurobiol; 2018 Nov; 55(11):8728-8737. PubMed ID: 29589283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
    Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
    Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.